A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Risankizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors AbbVie; Boehringer Ingelheim
  • Most Recent Events

    • 06 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2017 Trial has been completed in Czech Republic.
    • 05 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top